A decade of progress: Achievements and future challenges for regenerative medicine research in the United Kingdom

Journal of immunology and regenerative medicine Pub Date : 2024-03-11 DOI:10.1016/j.regen.2024.100078

Annabel J. Curle , Josephine L. Barnes , Robert Owen , Roger A. Barker , Alicia El Haj , Stuart J. Forbes , Cedric Ghevaert , Richard OC. Oreffo , Felicity RAJ. Rose , Molly M. Stevens , Zoe Hewitt

{"title":"A decade of progress: Achievements and future challenges for regenerative medicine research in the United Kingdom","authors":"Annabel J. Curle , Josephine L. Barnes , Robert Owen , Roger A. Barker , Alicia El Haj , Stuart J. Forbes , Cedric Ghevaert , Richard OC. Oreffo , Felicity RAJ. Rose , Molly M. Stevens , Zoe Hewitt","doi":"10.1016/j.regen.2024.100078","DOIUrl":null,"url":null,"abstract":"<div><p>The final United Kingdom Regenerative Medicine Platform (UKRMP) conference held in Edinburgh's iconic McEwan Hall between 8th and November 10, 2023 saw a gathering of nearly 200 international delegates presenting exceptional science and celebrating a decade of this initiative. The UKRMP had the core mission to break down the major barriers to clinical translation of regenerative medicine products. UKRMP2 was established as three hubs that worked closely with industry and regulators: 1) Pluripotent Stem Cells and Engineered Cells, 2) Engineered Cell Environments, and 3) Smart Materials. In this meeting report, we outline the original aims of UKRMP, examine how it achieved critical mass, summarise the major developments that the UKRMP hubs delivered, and examine some unresolved challenges that still lie ahead in the field of regenerative medicine.</p></div>","PeriodicalId":94333,"journal":{"name":"Journal of immunology and regenerative medicine","volume":"24 ","pages":"Article 100078"},"PeriodicalIF":0.0000,"publicationDate":"2024-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468498824000027/pdfft?md5=34a511e59647290cfb705cc6456747e9&pid=1-s2.0-S2468498824000027-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of immunology and regenerative medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468498824000027","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

The final United Kingdom Regenerative Medicine Platform (UKRMP) conference held in Edinburgh's iconic McEwan Hall between 8th and November 10, 2023 saw a gathering of nearly 200 international delegates presenting exceptional science and celebrating a decade of this initiative. The UKRMP had the core mission to break down the major barriers to clinical translation of regenerative medicine products. UKRMP2 was established as three hubs that worked closely with industry and regulators: 1) Pluripotent Stem Cells and Engineered Cells, 2) Engineered Cell Environments, and 3) Smart Materials. In this meeting report, we outline the original aims of UKRMP, examine how it achieved critical mass, summarise the major developments that the UKRMP hubs delivered, and examine some unresolved challenges that still lie ahead in the field of regenerative medicine.

查看原文本刊更多论文

十年进展：英国再生医学研究的成就与未来挑战

2023 年 11 月 8 日至 10 日，英国再生医学平台（UKRMP）在爱丁堡的标志性建筑麦克尤恩大厅举行了最后一次会议，近 200 名国际代表出席了会议，展示了卓越的科学成果，并庆祝这一倡议实施十年。UKRMP 的核心任务是打破再生医学产品临床转化的主要障碍。UKRMP2 设立了三个中心，与业界和监管机构密切合作：1）多能干细胞和工程细胞；2）工程细胞环境；3）智能材料。在本会议报告中，我们概述了英国再生医学计划的最初目标，研究了该计划如何达到临界质量，总结了英国再生医学计划中心取得的重大进展，并探讨了再生医学领域仍面临的一些尚未解决的挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of immunology and regenerative medicine

自引率

0.00%

发文量